Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
AKT1 207 MK-2206 CHEMBL1079175 inhibitor, allosteric modulator, inhibitory allosteric modulator ClearityFoundationClinicalTrial, TdgClinicalTrial, CKB, TALC, TTD, MyCancerGenome, MyCancerGenomeClinicalTrial, CancerCommons, ClearityFoundationBiomarkers, GuideToPharmacologyInteractions, ChemblInteractions 24265152, 25551293
AKT1 207 XL-418 CHEMBL3544935 inhibitor TdgClinicalTrial, ChemblInteractions, TTD
AKT1 207 RISPERIDONE CHEMBL85 PharmGKB
AKT1 207 NELFINAVIR CHEMBL584 inhibitor TALC
AKT1 207 EVEROLIMUS CHEMBL1908360 inhibitor CKB, CGI, MyCancerGenomeClinicalTrial
AKT1 207 OMIPALISIB CHEMBL1236962 inhibitor MyCancerGenomeClinicalTrial
AKT1 207 VEMURAFENIB CHEMBL1229517 CKB, CIViC 24265152
AKT1 207 UPROSERTIB CHEMBL3137336 inhibitor CKB, GuideToPharmacologyInteractions, ChemblInteractions 26429956, 23795919, 24978597, 24735930
AKT1 207 BAY-1125976 CHEMBL3545049 inhibitor CKB, ChemblInteractions 27699769
AKT1 207 PACLITAXEL CHEMBL428647 CKB
AKT1 207 SORAFENIB CHEMBL1336 CKB
AKT1 207 CHEMBL379218 CHEMBL379218 inhibitor GuideToPharmacologyInteractions
AKT1 207 ARSENIC TRIOXIDE CHEMBL1200978 inducer DrugBank 16239170, 12472888, 15916724, 15580309, 12529330
AKT1 207 CHEMBL23552 CHEMBL23552 DrugBank 17139284, 17016423
AKT1 207 AZD-5363 CHEMBL2178577 inhibitor MyCancerGenome, CIViC, CKB, OncoKB, ClearityFoundationClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions 26351323, 26931343, 28489509, 28376212, 22294718, 23394218
AKT1 207 TRICIRIBINE PHOSPHATE CHEMBL462018 inhibitor ChemblInteractions, TTD
AKT1 207 ARQ-092 CHEMBL3545422 inhibitor, allosteric modulator ClearityFoundationBiomarkers, CKB, GuideToPharmacologyInteractions, ChemblInteractions 26469692
AKT1 207 AZD-4547 CHEMBL3184679 inhibitor CKB, MyCancerGenomeClinicalTrial 26351323
AKT1 207 IRINOTECAN CHEMBL481 CKB 25714871
AKT1 207 MK-2201 CHEMBL3545000 inhibitor ChemblInteractions
AKT1 207 CHEMBL428963 CHEMBL428963 DrugBank 10592235
AKT1 207 CHEMBL259833 CHEMBL259833 DrugBank 10592235
AKT1 207 WORTMANNIN CHEMBL428496 NCI 10187855
AKT1 207 SIROLIMUS CHEMBL413 CKB 18708578
AKT1 207 TEMSIROLIMUS CHEMBL1201182 CKB 27016228
AKT1 207 APITOLISIB CHEMBL1922094 CKB
AKT1 207 GEMCITABINE CHEMBL888 CKB
AKT1 207 AFURESERTIB CHEMBL2219422 inhibitor GuideToPharmacologyInteractions, ChemblInteractions
AKT1 207 GSK-690693 CHEMBL494089 inhibitor GuideToPharmacologyInteractions, ChemblInteractions
AKT1 207 SR-13668 CHEMBL3545143 inhibitor ChemblInteractions
AKT1 207 LY-2780301 CHEMBL3545134 inhibitor ChemblInteractions
AKT1 207 MSC-2363318A CHEMBL3545003 inhibitor ChemblInteractions
AKT1 207 ADENOSINE TRIPHOSPHATE CHEMBL14249 DrugBank 17041888
AKT1 207 AFURESERTIB HYDROCHLORIDE CHEMBL2219423 ClearityFoundationClinicalTrial
AKT1 207 ENZASTAURIN CHEMBL300138 inhibitor TTD
AKT1 207 DOXORUBICIN CHEMBL53463 CKB 18708578
AKT1 207 CETUXIMAB CHEMBL1201577 CKB 25714871
AKT1 207 ALPELISIB CHEMBL2396661 CKB 27604488
AKT1 207 PICTILISIB CHEMBL521851 CKB 27604488
AKT1 207 A-443654 CHEMBL379300 inhibitor GuideToPharmacologyInteractions
AKT1 207 TRICIRIBINE CHEMBL331237 ClearityFoundationBiomarkers, TdgClinicalTrial, ClearityFoundationClinicalTrial, CKB 20644979
AKT1 207 PERIFOSINE CHEMBL372764 inhibitor TALC, TdgClinicalTrial, CKB, MyCancerGenomeClinicalTrial, TTD 25519148
AKT1 207 IPATASERTIB CHEMBL2177390 inhibitor MyCancerGenome, TdgClinicalTrial, ClearityFoundationClinicalTrial, CKB, GuideToPharmacologyInteractions, ChemblInteractions, MyCancerGenomeClinicalTrial, TTD 27872130

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
AKT1 rs2494732 TT risperidone efficacy yes Genotype TT is associated with increased response to risperidone in people with Schizophrenia as compared to genotypes CC + CT. 18855532 699638857
AKT1 rs3803300 CT risperidone efficacy yes Genotype CT is associated with increased response to risperidone in people with Schizophrenia as compared to genotype TT. 18855532 699638861
AKT1 rs2494750 GG carboplatin efficacy no No association was seen between this SNP and duration of progression free survival. Odds ratio below is for disease progression. Genotype GG is not associated with response to carboplatin or cisplatin in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + CG. 22901187 1183699173
AKT1 rs74090038 CC carboplatin efficacy no No association was seen between this SNP and duration of progression free survival. Odds ratio below is for disease progression. Genotype CC is not associated with response to carboplatin or cisplatin in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CT + TT. 22901187 1183699179
AKT1 rs2494752 AG carboplatin efficacy yes Subjects heterozygous for this variant showed significantly shorter progression free survival as compared to patients homozygous for either allele. Odds ratio below is for disease progression. Genotype AG is associated with decreased response to carboplatin or cisplatin in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + GG. 22901187 1183699139
AKT1 rs2498786 GG carboplatin efficacy no No association was seen between this SNP and duration of progression free survival. Odds ratio below is for disease progression. Genotype GG is not associated with response to carboplatin or cisplatin in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + CG. 22901187 1183699152
AKT1 rs2494732 T risperidone efficacy no Allele T is not associated with response to risperidone in people with Schizophrenia as compared to allele C. 28696411 1450928225
AKT1 rs3803300 C risperidone efficacy no Please note that alleles have been complemented to the positive strand. Allele C is not associated with response to risperidone in people with Schizophrenia as compared to allele T. 28696411 1450928233